HALO - Earnings call transcript Q1 2022 | Halozyme Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. My name is Emma, and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme First Quarter 2022 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. you. Thank Instructions] [Operator you your [ph], may Sharlene conference. begin Don

Unidentified Company Representative

our XXXX financial afternoon, and conference quarter to welcome Good results first call.

our Officer, that a In issued LaBrosse, addition Investor financial or President Nicole will slide call and update slide Relations find and Leading our Financial our in Torley, Halozyme's first Officer, will On today release with an referenced our business; Executive our presentation The both supplementary adjusted presentation. measures on review will Chief are the after the in reconciled earnings section non-GAAP and today's to the close, who you the results quarter. press our call non-GAAP provide who measures will be discussed. be financial press the comparable be will website. release for financial Helen measures GAAP GAAP during of today's can call, Chief and Dr. financial

you statements. we call, risks I'll the During call listing now of CEO, Torley. turn a over and refer will SEC the uncertainties. Helen the making forward-looking filings for our full to I to be our

Helen Torley

share provide and to also for in the industry close will with patients, and in Antares debt during standpoint. acquisition to the common to provides support financing team our an which diversification. also second you, our strengthens Halozyme and April, both to Thank the secured company lives structure. and very strong around She color capital track look her finance are Halozyme's drug remarks. the delivery the improve operational on stronger In We leader we is Antares innovating with Halozyme planned announced allocation growth start continue greater more and around will quarter. drive impact colleagues is very we acquisition even from as of favorable an a culture customers access an Pharma, acquisition about position This her to for revenue built have and forward same Don. mission excited and together a XXXX Antares that Nicole building patients. to of shareholders. a

progress earnings are and that delivered executional $X.XX revenue ENHANZE key capital per signing of earnings milestones. XXXX results strong maximize to these. growth X report of completion of our our share each the ENHANZE Chugai first QX for first is durability acquisition, first demonstration and grow to performance booking increase XXth continue progress of share what Shown are the by the with and excellence we of with This a These the revenue are royalty start we've on Halozyme. performance. operational reviewing continued and on of to on revenues capital quarter payment $X.XX. resulting our strategic growth of As through pleased year-over-year QX start to and associated is allocation priorities. to milestone Halozyme's and collaboration in We invest return a slide GAAP $XXX.X strong I'll Pharmaceutical. provided we adjusted driven non-GAAP ENHANZE our agreement our making million, the to reported XX% a to quarter to through I'm M&A. shareholders XXXX strong of quarter per Notably, Antares by

development ENHANZE to continue we highlight also will see portfolio. momentum we strong As in our

high-margin continues XXXX revenue we driven by to continued first million, $XX.X XX% royalties momentum, the over We're record had to Turning growth be we recurring successful, $XXX Janssen's Based ongoing growth XX% Phesgo. of representing sequential continued growth. of slide project This quarterly X. with revenue first DARZALEX global growth and in primarily the now growth stream. million. approximately XXXX delighted XX% of this an on approximately quarter, subcutaneous forms the Roche's with strong to launch royalty also quarter of by robust In the of growth

slide We commercialized markets currently approximately highlights globally. the that the patients five used technology. key provide these to to treat that have partner I'll are revenues. Turning global now in of It's than five. now are XXX drug estimated products have our commercialized products royalty that using to ENHANZE strong delivery products XXX,XXX contributing been more

ahead products drivers Phesgo Roche's Faspro royalty and Janssen's these growth Our continue and of growth Wave of two to I'll revenue on substantial each provide them. in the moment. additional DARZALEX opportunities current and for are each have color Subcu a

of or product. Herceptin commercialization in IV MabThera Roche ongoing its SC the project Hylecta. continues biosimilar Moving of result Hycela product. with also one related the and mature now products royalties is impact Rituxan these continued competition as We from the to which global called a to Wave Herceptin subcutaneous decline

Let shown me DARZALEX Slide with now details the two on on provide some Wave beginning product additional X.

including During by quarter and both the lines was therapy operational up which the all IV sales formulation and penetration year-over-year DARZALEX growth Janssen's billion Johnson subcutaneous $X.XXX of subcutaneous This Johnson XX.X% meaningful of on first an worldwide across primarily XXXX, all driven gains forms basis. of and regions. in was operational reported parent strong & share

the data. the subcu first on Symphony XX% increase to based from with attributed an subcu of XX% is being share continues December quarter This Faspro version U.S. DARZALEX on illustrated As slide, to the of grow XXXX. quarter in share in daratumumab share the end during

to Moving products. second two of the Wave our

one hours minutes. their from drive for million, reported up Roche quarter were two XXXX ago. delivery during quarter CHFXXX time monitoring and the that Sales first XXX% year XX by that with to to helping is a providing growth the approved from new of just partner products administration patients XX to overall patients a Phesgo decreases newly Our eight to the option from

result growth continued expect reimbursement launches We attained of strong accounts is Phesgo a oncology Europe in the United States. the World penetration continue to of Rest and ongoing in as quarter-over-quarter and of as through of

seven. slide to Moving

by to project will incremental royalty we potential discussed. that revenues new illustrate royalty the Wave those the by from two products resulting non-risk just that add we and grow projected we multiple how time, to Here in that evaluated neutralizing launches endpoint revenues waves Phase Phase one its to X new subcutaneous of at driven are in initiating of adjusted Efgartigimod four evaluating currently III of time and the this over royalty is I III met which And reminder, form as and the with four completed is additional five. antibody a NXLS announcement launches call and Wave studies. in brief prevention Myasthenia are Phase Each Wave products Roche and the our of comprised three study three XX for had three, Phase the advances Wave of treatment brings we This new These are currently products potential initiating X. primary included being second a us ENHANZE ENHANZE the which SC that these Gravis HIV. pivotal study ADAPT-SC study Generalized with [indiscernible] a their broadly revenues. Argenx closer

is non-inferior Let And me evaluated the has for total application adult now as being for We study, day Drug most subcu And of announced to ENHANZE Gravis. subcu was the met Drug our are Provided & Argenx on US currently as to Food Phase idiopathic ADVANCE IV Administration for subcutaneous which X XXXX Efgartigimod evaluating administered US plans The of Myasthenia potential potential the submit be Based on Argenx study, provide compared with thrombocytopenic that biologic the Efgartigimod in occur of with treatment treatment last to terrific in reduction which five the IV project with Argenx in IgG Efgartigimod intravenous Efgartigimod administration. to use. launches indications by it this at a its study ADAPT-SC Gravis. some with details & of XXXX XXXX. Efgartigimod. results partner endpoint ENHANZE. an anticipated the Generalized Administration results, congratulate stated primary in are by patients on XX approved XXXX. results will summary this these the Wave December launches demonstrating subcutaneously license positive purpura. administration end Slide approval the on evaluating we Efgartigimod week its advanced patients is Myastenia X is more of X is administration ADAPT-SC of this is in with track of which adult the with a and Food the that of between Efgartigimod first XXXX

later approved XXXX. XXXX Analysts of the at pace Slide XXXX. BMS's and attained. discussion have now with is to will as We indications, Phase expand X peak stages between to I'm nivolumab associated the overview to products and of are share IV consider now and X and May have total ENHANZE in started. launches the Ocrevus All for I'll drugs. cases atezolizumab potential It X the of is will the to that for that products Efgartigimod, atezolizumab to be Argenx' and Halozyme potential nivolumab, the IV is payments advance of shown Halozyme. that conversion pipeline first to also of These $XX launch with is Ocrevus these to set and has project Phase conversion and the billion development both We in of And partner Wave which me the Efgartigimod portfolio. with the X Roche's potential Wave to launch of the include to XXXX X a product, delivery four move this frame. exceed product goal the the development launch ENHANZE what as currently are call an Roche's in product and announce many our of now launch the from are products products the of formulations as slide XXXX for in begin potential development. of IV in study four key the development subcutaneous XXXX. be revenue subcu launch number bottom to this potential pleased revenue milestone we Let the and going continuously our our as to multiple subcutaneous of in as time

are XX slide. have Moving completed of testing. to top in Phase the the products currently or We clinical X have that

administered the prevention to a be broadly already technology. should the also during ViiV products Here NXLS X and Phase I'm ENHANZE of drugs is Wave range for of commercialized in we include X study launches. Phase our the of a a number diseases. quarter preceded NXLS, and report partner pleased our you the with evaluate subcutaneously and as will antibody HIV. And initiated also note, and and development treatment potential cover that utilizing be areas a safety pharmacokinetics X These ENHANZE successful therapeutic but of to

new four continue five or new for progress entering trial least clinic to at pipeline ENHANZE Looking XXXX, partner expect programs to and further and drugs Phase ahead project we X for products continue and X expansion Phase the year. this existing

me move Slide now to XX. Let

validating continue strengthening convenience, Pharmaceutical delighted As royalty I'm and collaboration to with licensing a R-XX, as for partner new growth, announced drive our long-term choice business further and we Halozyme, durable also patient that Chugai delivery. we a of drug subcutaneous agreement

product development a have our illustration, post of Wave revenue XXXX potential time X. an for as based adding growth entering As products, development lines XXXX part in launch ENHANZE on historical to would and the

Moving now to Slide XX.

have contributor deal strong Our remain to project Halozyme historically growth key and our progress, a revenues driven allocation pipeline capital this for we progress. and will and continue milestone new

have prior revenue meet As to the ranges. or met track you note, on guidance we can milestone three-year are

from million milestones in XXXX, $XXX period and development, three-year million commercial new milestones. mix XXXX total the a increase $XXX agreement expect we to For again of resulting to to milestones, to of

say Let acquisition. Antares move me few a words to regarding now,

licensing Just business revenue-generating a agreement royalty platform, growing and differentiated to proprietary commercial opportunities a with our that auto-injector acquire of consists Pharma, whose a three best-in-class ago, we new month announced products. offers business, Antares

with aligned and revenue, to growth each acquire ENHANZE to fulfills previously our on Antares slide XXXX further platform of growth to earnings to is perfect XXXX. center and shown a this, repurchases where XXXX. As additional and invest can and our to to expected XXXX, return technology, revenue is allocation be fully is this of to criteria. The revenue transaction accelerate while durability. Halozyme's Slide priorities These with our through and priorities durability, business transaction partner through growth for shareholders announced and drivers and the capital continue are to beyond line bottom XX, seek value development extending operationalize to adding for share non-GAAP our Halozyme and to capital create our the maximize top multiple accretive also a to at

In its for product in be We on Antares additional revenue technology place, technology molecule both of new to will revenues expect to expect XXXX and protections products. core drivers coming drive beyond, platform strong, XXXX. with build subcutaneous partnerships multiple partner growth to and beyond highly seeking sell in products large Antares' and small incremental, auto-injector opportunities, property capabilities administration form companies Antares' for intellectual from with we business, replacement growing and additive the durable,

With Slide XX. to as patient-convenient delivery. for position technology unlock combined the segments. team much and now that our leadership ENHANZE spectrum potentially call larger volumes of quarter widely injection complementary product of platform is our And to suite, financial Antares,' of drugs the to extends that a that successful Antares opportunities or We results. globally. our technology, for development forward Moving deliver expertise offers that, choice Nicole? new its The We're subcutaneously company a leveraging delivery further to first auto-injector drug allowing over to potential believe across broadly certain of a and subcutaneous market Nicole, partnership applied I'll patients of partner and discussion can to the help the to be injections. of turn faster a Halozyme, our very technology carries welcoming to licensable subcutaneous looking joint a treatment have

Nicole LaBrosse

for decrease a driven leverageable prior in the year growth XXXX us the period. non-GAAP compared Slide increase primarily $X.XX year The Helen. minimal million it's prior was highlights revenue of royalties some business I'll revenue period. driven the under to costs share was increase the earnings in driven On year-over-year an Operating the compared on agreements. quarter strong million of grow XX% XX, for collaborative $X.XX to sales you, to of quarter with focus GAAP the the per revenue million, million prior subcutaneous compared per million, of $XX.X to year-over-year basis, royalty start the by $XX.X recurring driven our was by, XX% quarter The $XX results. investments primarily year, product income in our DARZALEX the The from offset $X.XX diluted $XXX.X I'll in prior uptake increase Thank was increase note compared year enhanced. sales an was by year was of with million year the diluted period operating first Cost in compared first in first $X.XX is on year. the an share. XX%, overhead was allows model, comparing increase a expense, $XX.X quarter the manufacturing expenses. million to $X.XX period. representing prior in earnings prior the modest partially quarter where million This prior our despite per $XX.X for primarily of period. revenue revenue timing the was by in period. first compared recording period. a income $XX.X with to of utilizing Royalty decrease was product year year-over-year in in $XX.X of basis, continued by that in prior Janssen's Total is When share in which important to first On tax

me turn is our stand-alone for let review This a Now, of XX provided which what Halozyme's XXXX remains at the of guidance we guidance. slide financial beginning from unchanged to guidance are the provide year a transaction closes updated the combined. plan not any guidance two call and companies at quarterly to Antares and from including does Antares. contribution the after include We

year $XXX full XXXX, million representing total to to to continue XX% over of of revenue. we total expect the million, For XX% $XXX XXXX growth revenues

what expected increase revenues to for terms and XXXX Product from $XXX components to our balanced expect to XXXX API substantially royalties levels XXXX from being partner similar for approximately throughout are the year revenues sales achieved second at weighted more royalties of expected revenue the we on in over million. in the approximately in we milestone-bearing our XX% total based collaborative milestones year of with to half events. and the In timing be revenue, in of

representing ENHANCE growth important incremental investment, this we includes million $XXX operating Even maximize expense $XXX to an durability. revenue margins than over royalty XX% income and operating XX%. XX% operating extend investment $XX of This million expect to with income. of greater expect million, We XXXX of operating to

and Moving our allocation slide priorities. to summary XX a of capital now

capital debt, We of and have a of plans Antares in using us put to mix priorities capital committed allocation been an consistent our acquire shareholders. regarding advantageous while our which to return to balanced position cash remaining

Our balance strengthening position further sheet and December remains XX, million securities on $XXX.X million XXst to prepare to financial our on XXXX we as strong transaction. with marketable cash, compared cash of XXXX, the equivalents, Antares $XXX.X close March

the of debt market low-cost with We are the terms to finance in transaction the and access non-diluted to and pleased demand rata bank financing. able are pro this favorable

we approximately expected the debt-to-EBITDA ratio the maintain a in stated, X.X to significant quarters a close. the decline time at times projected of with we expect with sheet strong As following balance close net

maintain XXXX. While execute will our accelerated on a we announced $XXX previously million program, $XXX December in million also will repurchase share program, initiated inclusive we three-year focus of repurchase deleveraging, share on continue to

continue million to and in on With back Helen. to up conditions to I'll in share factors. market plan other additional that, dependent turn now We the for an $XXX XXXX, repurchases call

Helen Torley

like that, take please strong for income we'd our In partners strong by Halozyme and everyone this resulting expanding joining growing performance in to questions? with Operator, Nicole. all I'd long-term operating questions. be today. thank open for that your collaborators now like growth. revenues, for of growing near-term to deliver delighted you, pipeline our us XXXX, I'd hard to Thank quarter. the call the will team, our we and the you in close our to And both work resulted thanking, and continue would

Operator

from comes today Cantor line Fitzgerald. the Duncan question with first Your Instructions] Charles [Operator of

now is line open. Your

Charles Duncan

and and progress. good on congratulations Thanks questions afternoon, Nicole. Helen my Good for a quarter taking of Okay.

Helen Torley

Thank you.

Charles Duncan

Yeah.

One DARZALEX SC. questions. of on couple a had is I So

heard you now. And say XX% -- I can anyone be you guess, than go? version? higher not would the anticipated. pretty that that's over had I terms would what think to SC that, And In do convert of we that's I high, SC think conversion Where reason the actually

Helen Torley

that. Charles Sure. Thanks for

find quarter about the first did in the So, XX% end that yes, we United at indeed was share. of the the States, conversion

why But see patients in Now, we comfortable may and convert it to the may we the United about that year being very was grow there who continually a outside the anecdotally update that. the infusion or aspect will number do the to well. specific share of suite, when phobia knew go since we small are I about And as say social wouldn't of provided U.S. needle reasons of has that hear be higher. in do U.S. opportunity of have any on the we a would bit. think be the people last the middle States lagging importantly, not because Janssen

brand by So the as U.S. continued the continued conviction time expect growing continued got be a, to to projected. Charles, talked gains we as well and but just overall why growth January is overall we come. this growth in we're pleased see very brand what It's in share the year driven growing the you U.S. also we've growth get of we some recall throughout as well. And outside that for as such because, the had going confidence if about SC which I'll share to the comment

Charles Duncan

conversion pace peak that wondering, data Helen, I Generalized from in could the for of Wave guess, as Gravis. on IV? potential And there. may interested perspective relate regarding I'm drug ultimate the But Okay. Efgartigimod you, the That's I in to particularly especially share ask proposition, the if with to I'm Myasthenia of then, it us value X. and wanted recent you and your helpful. Congrats

Helen Torley

Yeah.

new remarks very see anyone Argenx hope subcu said start. offering the we were a absolutely, new And to reported very pleased data for action IV also we to of importantly, launch prepared as the Efgartigimod is mechanism listening of who was patients. for the obviously this in positive and the is for So a that off strong

IV year. the off the to is all data of end So, be this by taking very the to see expected filed well, good subcu

clinical value proposition opportunity offer does preference XX% a more looking lengthy the IV. patients received for to for So Argenx' who quick in patients And injection the patients in non-complex and SC XXXX launch. opposed a we're expressed subcu on for the comments as the based And both of we of at their subcu. do terms subcutaneous the studies a for IV know

office one many high that to have strong IV is more chance to going where comfortable environment. do see that very and observed drugs in see the physicians this used we a be dynamics so to company as so And growingly competitive what perhaps proposition is the we motivated be a giving for we And We what see DARZALEX. setting and are similar market with a are subcu an we than success where very going that to patients. to see is value

the but we to specifically as support we give once-weekly given Gravis the Generalized think what specific the does unmet everything convenience subcu don't and guidance of be the the using Myasthenia conversion think So, excitement a to Efgartigimod I regimen. is, or and rate patients need in

Charles Duncan

Could a my taking game good. changer. be Thanks for Very questions. neurology

Helen Torley

you. Thank

Operator

Your comes from DiFiore of the Mike next Evercore. line with question

Your line open. is now

Mike DiFiore

cadence me. rest for on of if color actual guys. factors for the launch could so additional EU And US for if of provide a also, the lumpy Phesgo, the Thanks Phesgo continued Two questions. And the reimbursement gating of throughout will evenly I it Hi, be there's One year distributed? follow-up. on growth? or have taking my ex-US more in you much any

Helen Torley

right. All

that, top is the within to used months, months. XX companies, ticking sure be that that the up For or hearing that to companies would get sometimes other reimbursement as six you launches be it do we could five ex-US you I'm from Mike XX know may all while consider

some European has the launched. provided that, we specific know markets larger of Roche traditionally not can that comments have we that, so but on not And say yet

two to And so up taking is that years.

to markets strong more accounts So Roche with with that far, the predict on come. And then States on conversations we're United continued is do based performance of as and some major this so why yet coming growth is Europe, excited continued into we traditional the accounts penetration new well for the but in about board.

throughout a is gradually question of and the we have that year. projected this growth year So, the the to adding for growing quarter-on-quarter them

Mike DiFiore

And question the regarding Okay. Very final acquisition. you. my is helpful. Thank Antares

not and XXXX, comment the on may able early Antares guys commented was actual divest? to Any call, during Do – XXXX, if would XXXX. You be then something this, helpful? acquisition will you the sure, has and this on you very to not I'm assets incurring expense, three but more intend those that deal but or be be develop those R&D thereby color along those lines some

Helen Torley

And is in certainly Yeah. diligence. is the did will and understand. I acquisition pleased an we area integration streams integration. before say seeking digging Thank you. Mike what our very making the in the we We're we're Obviously and program on where work I'm R&D progress to continuing are with

and decisions we a These made with one R&D making really look work that. traditional the obviously or no costly Antares So programs on of is say sure ANDA understanding post-close I follow lot that lot -- forward here have these faster colleagues we pathways, full which differentiation continuing and a on less expense. development. to will XXX(b)(X) to than tend drug a are to

in look at these for obviously no decisions of we investment which with areas, each be need is interesting would as exist and area but going into very much is an yet. potential opportunities look taking each we're that of unmet at return of consideration So the something that to as these

Mike DiFiore

much. helpful. very you Very Thank Great.

Helen Torley

you. Thank

Operator

the of from Sachs. Corinne line comes question with next Your Jenkins Goldman

open. now Your line is

Corinne Jenkins

Good afternoon everybody.

lot about the that what think So thinking we've some injection the when I of and keep for FASPRO some next obviously with And of ENHANZE has upside. quite research potential a launch conversion mind bear? efgartigimod, about should you in that the the bring been the versus people surprised are there? products conversion about as seen the think revealed the to factors we others your the market market has probably we high co-formulation But to of in use what appetite subcutaneous

Helen Torley

Efgartigimod efgartigimod of I'll made refer do you. the to competition an present And are And obviously I looking argenx in with that comments are of the back think drivers products. year It's between area DARZALEX Thank competition successful. where product similarities in DARZALEX and coming FcRn lot very also opportunity market the there some where be into Yeah. form to are see earlier is Efgartigimod we opportunity. or and additional the today of of specifically important for a CX a we both the but

having a convenient of cite the not I possible ourselves but any most going So factor. important done winning is detailed strategy we've with think Corinne, we be comments very research market therapy can a to type after that argenx has both made subcu to expressed on subcu, preference the patients receiving both and XX% in received study for calls where IV forms the of patients say that their a clinical of therapy.

offices, the here not set is are who therapy. treatment fact happening rheumatologist offices So of for up that immunologist in and IV factors these with necessarily the all

just very robust We So we of a well to patients. this think very I'll is uptake. all factors the those subcu believe is speaks on finish that conducive delivery. to saying drug And

a You short infusions patient preference versus simple the have injection delivered we long-IV strong to with cetera, subcu imagine a patient for chronic as think et IVs a ability here disease, winning well. can there's

Corinne Jenkins

And just the you first said what you Great. understand can Thank in respect you. -- probably half the complete That's helpful. completing this think to us Antares steps I year? help second the that deal remain of then half with to acquisition,

Helen Torley

reviews tender Yes. Corinne. regulatory at the completion perhaps the include This not also offer

could just satisfactorily And point well XXXX two based the in the conditions the wait completed is be say but close. we time. that time be we before earliest would to those can close for we've mentioned So this as as of completion on can at progressing the everything to got transaction regulatory areas reviews I

Corinne Jenkins

you. Thank

Operator

the of Your with Fye JPM comes line next question Chase. Jessica from

line is Your open. now

Jessica Fye

my for auto-injector for lastly and and And delivery so? questions. taking then be drugs subcu with would much how guys, Could afternoon. for Janssen candidate work the year, a be ViiV? this returning Hey to repo? the if Thanks good some thinking about Efgartigimod will HIV required kind via paying close, Antares share following provided prioritize acquisition 'XX after debt of recognizing the versus in beyond you've down shareholders and commentary repo cash share you how What that about

Helen Torley

it the Let and might questions their plan partners debt. take -- to closed then transaction with me the Yes at and do a the look is auto-injector the the engage for to we match auto-injector. pass to see on once for Nicole paying all if of obviously there I'll our take a be portfolios down question of

the a would important access transaction close, potential announced when to developing volume we as a most auto-injector. a excited be very we're one thing be X But of have auto-injector. immediately the going the to stated ml is we ml the ml we to X.XX the about think I and injection upon

So and comment be on certainly we in delivered portfolio, are in doing can transaction the volume ml. currently the products see for premature opportunity of in both a to that up for molecules but biologics this X any specifically to that small

is lot believe. opportunity of there a we So, out there

Nicole LaBrosse

And I'm happy question to cover Jessica. your second

priorities remain our So regards in capital allocation they do to unchanged.

our on plan are in for progress year able the continue availability we're is And are we at flow debt just as of quarters $XXX to we via of do plan purchase the quickly plans both which projecting still address coming projections. do really moment, well to the we the our end inclusive plans. three-year well we to driven an our mentioned again repurchase be deleverage that at that on million million acquisition $XXX all the project objectives Antares ASR as are and of here to taking cash as which by we of we announced those but So, in to share strong the with track last

Jessica Fye

you. Thank Great.

Operator

of line comes from question Markets. Berenberg Anita next Dushyanth Capital the with Your

Your is now open. line

Anita Dushyanth

guidance afternoon. good question. obviously can for you ask second not Hi, in the be you've I the my Thanks about the year? now Helen that updated the from include taking towards half would assets does but half the of provided Antares, first post-closing

Helen Torley

Yes on call our it at earnings to to provide the after next intention is the guidance. update -- an close

Anita Dushyanth

also at pharma Okay. partnership one I annually mean HALO has the on Great. partnerships And signed least regarding historically players. with your

auto-injector or on preference signing of or going you would partnerships there remain or kind ENHANZE So, agnostic? a forward, towards using be

Helen Torley

ENHANZE think three great now seek a the segments ml. how going that to only. exciting X looking us that It's opportunity for X.XX and have question volume we're I address is only we that opportunity post we and what to assess I Antares. buckets is really at see auto-injector the that ENHANZE small be the is would and close and as Auto-injector And probably we're plus do

three Halozyme where areas, have to all see create new we the potential deals. So

Anita Dushyanth

Great. Thank you.

Operator

Securities. comes today question of from last Butler with Jason line Your JMP the

line Your now open. is

Unidentified Analyst

ml. Thanks remains compatible our lines how auto-injectors to questions. had do I think to HI, for And it's gating straightforward to be? ml? generally guess be the going few preliminary taking X And viscosity that the a to get work on that Roy will option you you [ph] your for what time what on it X in Jason. I Thanks. think are with high And the the do based get available? is formulations?

Helen Torley

do able be premature that to we viscosity. to me we Thanks, range Roy, for specifically, and that will comment questions a expect Yes. deliver little of all a able to great still is be work but

a volume priority the excited do provide be great very Antares moving seen and what marketplace regard we've for the this bit spend going the time build with for cetera plans. large team seen ENHANZE forward with time important unique more together some us is us. testing But far. after Antares the of to really want technology in et ml feasibility with So be able like the to will which a offering We've this. And work close a we subcutaneously. X out in the with so to that's we to a specific think terms very to to those deliver thing line, a But

Unidentified Analyst

Very good. Thanks. it. Got

Operator

the questions There Helen you. this time. call I are Torley, back turn further at no over to

Helen Torley

very you provide Thank attention Lovely. Obviously, we you start further with look you close able updates for thank transaction much in very Antares off later we're support. very Well, to to for your on to Thank Goodbye. a year. QX joining today strong much. QX. this us forward and and We our the everybody. the call of being and everybody

Operator

today's concludes call. conference This

disconnect. now may You

Halozyme Therapeutics (HALO) 11 May 222022 Q1 Earnings call transcript